Union of forces advances myeloma care
Keyword(s):
In this issue of Blood, Richardson et al report on a landmark treatment regimen for newly diagnosed myeloma patients that for the first time combines lenalidomide and bortezomib. This effort required a team approach comprising 2 competing pharmaceutical companies (joining forces to study this promising regimen) and multiple academic medical centers.1
2016 ◽
Vol 111
◽
pp. S134-S135
Keyword(s):
2006 ◽
Vol 2006
◽
pp. 221-222
Keyword(s):
Keyword(s):
2009 ◽
Vol 11
(12)
◽
pp. 695-697
◽
Keyword(s):
Bridging Leadership Roles in Quality and Patient Safety: Experience of 6 US Academic Medical Centers
2017 ◽
Vol 9
(1)
◽
pp. 9-13
◽